28 June 2019 - - US-based molecular diagnostics company Co-Diagnostics, Inc. (NASDAQ: CODX) has named Dr. Eugene Durenard and Ted Murphy to its board of directors, the company said.
They will serve on the board's compensation and corporate governance/nominating committees and audit committees as independent directors.
Dr. Durenard brings a thorough multi-asset class investment and entrepreneurial experience spanning 20 years to the board of directors.
He is the founder and CEO of Hyperbolic Holdings, a Swiss-based holding, management consulting and investment advisory company specialised in healthcare since February 2018; co-founder and CIO of Healthcare Impact Holdings, an investment fund specialised in later-stage healthcare private ventures since May 2018; co-founder and trustee of Healthcare Impact Foundation, a charitable organisation designed to sustainably fund translation of innovation in life sciences since September 2017; co-founder of Global Better Health, a platform designed to provide scientifically-based corporate wellness and preventive programs since December 2018; and an advisor to and Managing director of the Stetson Family Office since September 2016. Dr. Durenard received his PhD in Mathematics at Harvard in 1995 before beginning his career with Salomon Brothers in London.
Murphy has been senior partner in a private investment firm from June 1999 to the present. His duties have included investment analysis of various types of investment projects in health care, real estate and financial services.
Murphy serves on the board of directors of three Canadian publicly reporting companies that have interests in various industries.
Co-Diagnostics, a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new diagnostics technology.
The company's technology is utilised for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.